KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancerPrabhakar Pitta Venkata(Unknown), Gangadhara R. Sareddy(The University of Texas at San Antonio Health Science Center)Cancer LettersOctober 19, 202110.1016/j.canlet.2021.10.019Cited by 19SaveCiteExport RISWatch citationsRelated PapersSelective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma|Scientific Reports|2016|71Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer|Oncotarget|2017|43Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer|Cancer Letters|2023|18Reticulocalbin 3 Is a Novel Mediator of Glioblastoma Progression|Cancers|2023|5